FUSHILAI(301258.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
FUSHILAI
301258.SZ
Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; l-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonsteroidal anti-inflammatory analgesic used to relieve the pain symptoms of osteoarthritis. Its products are used in medicines, dietary supplements, and cosmetics applications. The company also engages in research and experimental development and capital market activities.
3.125 T
301258.SZMarket value -Rank by Market Cap -/-

Financial Score

21/01/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking162/222
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.99%C
    • Profit Margin17.28%A
    • Gross Margin13.63%D
  • Growth ScoreB
    • Revenue YoY6.39%C
    • Net Profit YoY302.42%A
    • Total Assets YoY3.56%C
    • Net Assets YoY0.98%C
  • Cash ScoreC
    • Cash Flow Margin578.69%C
    • OCF YoY6.39%C
  • Operating ScoreD
    • Turnover0.21D
  • Debt ScoreA
    • Gearing Ratio11.27%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    FUSHILAI released its performance for the first three quarters, with a net profit attributable to the parent company of 73.3966 million yuan, an increase of 430.16%

    FUSHILAI released its third-quarter report for 2025, with operating revenue of 323 million yuan in the first three quarters, a year-on-year increase of 3.23%. The net profit attributable to the parent company was 73.3966 million yuan, a year-on-year increase of 430.16%. The net profit after deducting non-recurring gains and losses was 2.5119 million yuan, a year-on-year increase of 119.80%. The basic earnings per share were 0.8099 yuan

    Zhitong·
    SZ
    301258
    -0.21%
    Zhitong·
    SZ
    301258
    -0.21%

    FUSHILAI: Cumulatively repurchased 950,000 shares

    FUSHILAI announced that as of August 15, 2025, the company has cumulatively repurchased 950,000 shares through a dedicated securities account for stock repurchase via centralized bidding, accounting for 1.0363% of the company's current total share capital, with a highest transaction price of 38.56 yuan/share and a lowest transaction price of 33.04 yuan/share, totaling a fund amount of 33.9052 million yuan. The company's repurchase complies with relevant laws and regulations and the established share repurchase plan

    Zhitong·
    SZ
    301258
    -0.21%
    Zhitong·
    SZ
    301258
    -0.21%

    FUSHILAI: The total number of shares repurchased by the company is 400,000 shares

    FUSHILAI announced that as of July 31, 2025, the company has repurchased a total of 400,000 shares through a dedicated securities account for stock repurchase via centralized bidding, accounting for 0.4363% of the company's current total share capital, with a highest transaction price of 35.72 yuan/share, a lowest transaction price of 33.04 yuan/share, and a total amount of funds used of 13.8157 million yuan. The company's repurchase complies with relevant laws and regulations and the established share repurchase plan

    Zhitong·
    SZ
    301258
    -0.21%
    Zhitong·
    SZ
    301258
    -0.21%

    Pharmaceutical stocks continue to be strong, FUSHILAI hits the 20% limit up, Tuoxin Pharmaceutical and Cosunter rise over 10%, Xizang Weixinkang Pharmaceutical, MEDISAN and several other stocks hit the limit up

    Zhitong·
    SZ
    301258
    -0.21%
    SZ
    301089
    +0.10%
    SZ
    300436
    +0.99%
    Zhitong·
    SZ
    301258
    -0.21%
    SZ
    301089
    +0.10%
    SZ
    300436
    +0.99%

    FUSHILAI plans to spend between 20 million and 40 million yuan to implement a buyback

    According to the Zhitong Finance APP, FUSHILAI announced that the company plans to use its own funds to repurchase company shares for the implementation of an equity incentive plan or employee stock ownership plan. The total amount of funds for the share repurchase will not be less than 20 million yuan (inclusive) and not exceed 40 million yuan (inclusive), with the repurchase price not exceeding 40 yuan per share (inclusive). The implementation period for the share repurchase will be within 12 months from the date the company's board of directors approves this repurchase plan

    Zhitong·
    SZ
    301258
    -0.21%
    Zhitong·
    SZ
    301258
    -0.21%
    © 2026 Longbridge｜Disclaimer